PDCD1 and neoplasm: A clinical trial showed that tumors that were exposed to single-dose trastuzumab had an increased immune presence, including PD-1 positive TILs in 17–40% HER2 tumors, which suggested that trastuzumab might directly elicit specific tumor immune responses in a subset of tumors [23].